Deaths prompt revisions in Japanese precautions for dabigatran
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has strengthened the safety warnings and use precautions for its novel anticoagulant Prazaxa (dabigatran etexilate) in Japan following the deaths of five patients receiving the product.